Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAZOPANIB Efficacy and Tolerance in Desmoids Tumors : Phase 2 Clinical Trial

Trial Profile

PAZOPANIB Efficacy and Tolerance in Desmoids Tumors : Phase 2 Clinical Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Methotrexate; Pazopanib; Vinblastine
  • Indications Fibroma
  • Focus Therapeutic Use
  • Acronyms DESMOPAZ
  • Most Recent Events

    • 19 Jun 2018 New trial record
    • 05 Jun 2018 Primary endpoint (Efficacy evaluation in terms of non progression rate at 6 months of treatment methotrexate-vinblastine) has been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Primary endpoint (Efficacy evaluation in terms of non progression rate at 6 months of treatment with Pazopanib) has been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top